These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 29227878)

  • 21. What about us? Recent advances in the treatment of chronic hepatitis C threaten to leave some parts of the world behind.
    Ahmed F
    J Viral Hepat; 2013 May; 20(5):367-8. PubMed ID: 23565620
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin.
    Waizmann M; Ackermann G
    J Subst Abuse Treat; 2010 Jun; 38(4):338-45. PubMed ID: 20362408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Substitution treatment or active intravenous drug use should not be contraindications for antiviral treatment in drug users with chronic hepatitis C.
    Manolakopoulos S; Deutsch MJ; Anagnostou O; Karatapanis S; Tiniakou E; Papatheodoridis GV; Georgiou E; Manesis E; Tzourmakliotis D; Archimandritis AJ
    Liver Int; 2010 Nov; 30(10):1454-60. PubMed ID: 20846344
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis C prevention and true harm reduction.
    Madden A; Cavalieri W
    Int J Drug Policy; 2007 Oct; 18(5):335-7. PubMed ID: 17854719
    [No Abstract]   [Full Text] [Related]  

  • 25. High prevalence of late relapse and reinfection in prisoners treated for chronic hepatitis C.
    Bate JP; Colman AJ; Frost PJ; Shaw DR; Harley HA
    J Gastroenterol Hepatol; 2010 Jul; 25(7):1276-80. PubMed ID: 20594255
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis C: An Eastern Perspective.
    Dan YY; Lim SG
    Gastroenterol Clin North Am; 2015 Dec; 44(4):793-805. PubMed ID: 26600220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Scale-up of hepatitis C treatment in prisons is key to national elimination.
    Papaluca T; Hellard ME; Thompson AJV; Lloyd AR
    Med J Aust; 2019 May; 210(9):391-393.e1. PubMed ID: 30968417
    [No Abstract]   [Full Text] [Related]  

  • 28. Injecting drug use: A vector for the introduction of new hepatitis C virus genotypes.
    Ruta S; Cernescu C
    World J Gastroenterol; 2015 Oct; 21(38):10811-23. PubMed ID: 26478672
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug-drug interactions in the treatment of HCV among people who inject drugs.
    Mauss S; Klinker H
    Clin Infect Dis; 2013 Aug; 57 Suppl 2():S125-8. PubMed ID: 23884060
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low incidence of reinfection with the hepatitis C virus following treatment in active drug users in Amsterdam.
    Grady BP; Vanhommerig JW; Schinkel J; Weegink CJ; Bruisten SM; Lindenburg CE; Prins M
    Eur J Gastroenterol Hepatol; 2012 Nov; 24(11):1302-7. PubMed ID: 22825643
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapid virological response in hepatitis C virus genotype 1 and early ribavirin exposure.
    Dai CY; Chuang WL; Huang JF; Hsieh MY; Yu ML
    Hepatology; 2008 Aug; 48(2):692-3; author reply 693-4. PubMed ID: 18666250
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment of chronic hepatitis C in active drug users.
    Davis GL; Rodrigue JR
    N Engl J Med; 2001 Jul; 345(3):215-7. PubMed ID: 11463020
    [No Abstract]   [Full Text] [Related]  

  • 33. Relapse to opioid use after treatment of chronic hepatitis C with pegylated interferon and ribavirin.
    Matthews AM; Fireman M; Zucker B; Sobel M; Hauser P
    Am J Psychiatry; 2006 Aug; 163(8):1342-7; quiz 1479. PubMed ID: 16877644
    [No Abstract]   [Full Text] [Related]  

  • 34. High HIV and HCV and the unmet needs of people who inject drugs in Yerevan, Armenia.
    Johnston L; Grigoryan S; Papoyan A; Grigoryan T; Balayan T; Zohrabyan L
    Int J Drug Policy; 2014 Jul; 25(4):740-3. PubMed ID: 24612640
    [No Abstract]   [Full Text] [Related]  

  • 35. Prisons, prisoners, and hepatitis C.
    Ferguson L; Batey R
    J Gastroenterol Hepatol; 2010 Jul; 25(7):1184-6. PubMed ID: 20594243
    [No Abstract]   [Full Text] [Related]  

  • 36. Hepatitis C: Unfolding the Challenges.
    Reddy KR
    Gastroenterol Clin North Am; 2015 Dec; 44(4):xv-xvi. PubMed ID: 26600229
    [No Abstract]   [Full Text] [Related]  

  • 37. The physical health of people who inject drugs: complexities, challenges, and continuity.
    Cornford C; Close H
    Br J Gen Pract; 2016 Jun; 66(647):286-7. PubMed ID: 27231287
    [No Abstract]   [Full Text] [Related]  

  • 38. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting.
    Read P; Lothian R; Chronister K; Gilliver R; Kearley J; Dore GJ; van Beek I
    Int J Drug Policy; 2017 Sep; 47():209-215. PubMed ID: 28587943
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiviral treatment for chronic hepatitis C in illicit drug users: a systematic review.
    Zanini B; Lanzini A
    Antivir Ther; 2009; 14(4):467-79. PubMed ID: 19578232
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Harm reduction interventions should encompass people who inject image and performance enhancing drugs.
    McVeigh J; Kimergård A; Bates G; Hope VD; Ncube F
    BMJ; 2016 Apr; 353():i1889. PubMed ID: 27048560
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.